

## **Director Clinical Science / Medical Director**

**A central position in an early phase biotech, focused on cancer and immunotherapy.**

### **Principal Responsibilities:**

Drive the development and successful execution of clinical research strategies to clearly define the benefit-to-risk profile of our products. Give scientific/medical input to clinical protocol design and study objectives, as well as ongoing clinical assessments.

Represent PCI Biotech science and clinical development expertise to external (investigator, academic, partner, regulatory, and medical) communities. Work closely with our international scientific and medical advisors on strategies for clinical and translational research.

Serve as lead internal author for scientific publication of clinical development studies. Deliver the clinical sections of regulatory documents.

Provide scientific and medical input to other R&D and business development functions.

Reporting to Chief Executive Officer.

### **Qualifications:**

MD or PhD in a health related science with research and industry experience;

- Solid experience from the immunology and preferably also the oncology field
- Experience and solid understanding of clinical research and pharmaceutical product development
- Experience and/or understanding of how to translate science into treatment opportunities
- Understanding of scientific methods and clinical applications based on medical, scientific and practical rationale

### **Other qualifications:**

- Analytical and structured
- Independent and result oriented
- High integrity and work capacity
- Innovative, flexible and proactive
- Good communication skills in English and preferably in Norwegian or other Scandinavian language
- Able to travel

**Application deadline:** 15. August 2015

Please contact **CEO Per Walday** for further information about the position:

Phone: +47 91793429

e-mail: [per.walday@pcibiotech.no](mailto:per.walday@pcibiotech.no)

## About PCI Biotech

PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange (Axsess). The company is developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI technology works by inducing triggered endosomal release and may be used to unlock the true potential of a wide array of therapeutic modalities, such as small molecules, vaccines and nucleic acids.

The company currently has a bile duct cancer program in phase I/II clinical development. Bile duct cancer is an orphan indication without any approved medicinal products and a high medical need for better local treatments. It is an indication well suited for PCI treatment, with easy light access for intraluminal surface illumination through routine endoscopic methods and an active generic drug (gemcitabine) significantly enhanced by PCI.

The company is also developing PCI as a CTL (Cytotoxic T Lymphocyte) induction technology for therapeutic and prophylactic vaccination. It has been demonstrated both in vivo and ex vivo that PCI significantly increases the number of activated antigen-specific CTLs by enhancing the MHC I antigen presentation of antigen presenting cells. When applied in the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines.

PCI Biotech follows a strategy to create value by improving the effect both of existing cancer drugs and by realizing the large potential in new therapeutics, including therapeutic vaccines.